University of Vermont

The University of Vermont Cancer Center

trials_pedhemat

Pediatric Hematological Clinical Trials

The University of Vermont Cancer Center has many trials specifically focused on pediatric hematological research.

Status: Active - Recruiting
Study Title: ALinC 17: Protocol for Patients with Standard Risk Acute Lymphoblastic Leukemia - A Phase III Study
Purpose: This randomized phase III trial is comparing four regimens of combination chemotherapy to see how well they work in treating children with newly diagnosed acute lymphoblastic leukemia.
ClinicalTrials.gov Identifier: NCT00005596
Primary/Site/Co Investigator: Alan C Homans
Contact: Alan Homans (802) 847-2850
Information: http://www.clinicaltrials.gov/ct2/show/NCT00005596?term=00005596&rank=1
Institution Number: 80-1 POG 9905
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title: AALL11B1: A Phase III Randomized Trial for Newly-Diagnosed High-Risk B-Precusor Acute Lymphoblastic Leukemia
Purpose: This randomized phase III trial is studying how well combination chemotherapy works in treating young patients with newly diagnosed high-risk acute lymphoblastic leukemia.
ClinicalTrials.gov Identifier: NCT01406756
Primary/Site/Co Investigator: Alan C Homans
Contact: Alan Homans (802) 847-2850
Information: http://www.clinicaltrials.gov/ct2/show/NCT01406756?term=01406756&rank=1
Institution Number: 80-1 POG C9710
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title: AALL08B1: Classification of Newly-Diagnosed Acute Lymphoblastic Leukemia
Purpose: This research study is developing a risk-based classification system for patients with newly diagnosed acute lymphoblastic leukemia.
ClinicalTrials.gov Identifier: NCT01142427
Primary/Site/Co Investigator: Alan C Homans
Contact: Alan Homans (802) 847-2850
Information: http://www.clinicaltrials.gov/ct2/show/NCT01142427?term=01142427&rank=1
Institution Number: 80-1 POG C9710
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title: AALL06B1: Infant Acute Lymphoblastic Leukemia
Purpose: This phase III trial is studying giving lestaurtinib together with combination chemotherapy to see how well it works compared to combination chemotherapy alone in treating infants with newly diagnosed acute lymphoblastic leukemia.
ClinicalTrials.gov Identifier: NCT00557193
Primary/Site/Co Investigator: Alan C Homans
Contact:Alan Homans (802) 847-2850
Information: http://www.clinicaltrials.gov/ct2/show/NCT00557193?term=00557193&rank=1
Institution Number: 80-1 POG C9710
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title: AALL10B1: Acute Myeloid Leukemia
Purpose: This randomized phase II/III trial is studying how well giving bortezomib and sorafenib tosylate together works in treating patients with newly diagnosed acute myeloid leukemia with or without mutations. Bortezomib and sorafenib tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Giving bortezomib and sorafenib tosylate together with combination chemotherapy may be an effective treatment for acute myeloid leukemia
ClinicalTrials.gov Identifier: NCT01371981
Primary/Site/Co Investigator: Alan C Homans
Contact:Alan Homans (802) 847-2850
Information: http://www.clinicaltrials.gov/ct2/show/NCT01371981?term=01371981&rank=1
Institution Number: 80-1 POG C9710
Protocol Research Type: Cooperative Group

Last modified December 05 2014 11:49 AM